NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma

BACKGROUND: There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and temozolomide in patients with glioblastoma aged 65 years and older. METHODS: NUTME...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Hao-Wen, Wachsmuth, Luke, Barnes, Elizabeth H, Yip, Sonia, Koh, Eng-Siew, Hall, Merryn, Jennens, Ross, Ashley, David M, Verhaak, Roel G, Heimberger, Amy B, Rosenthal, Mark A, Hovey, Elizabeth J, Ellingson, Benjamin M, Tognela, Annette, Gan, Hui K, Wheeler, Helen, Back, Michael, McDonald, Kerrie L, Long, Anne, Cuff, Katharine, Begbie, Stephen, Gedye, Craig, Mislang, Anna, Le, Hien, Johnson, Margaret O, Kong, Benjamin Y, Simes, John R, Lwin, Zarnie, Khasraw, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576515/
https://www.ncbi.nlm.nih.gov/pubmed/37841696
http://dx.doi.org/10.1093/noajnl/vdad124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576515/
https://www.ncbi.nlm.nih.gov/pubmed/37841696
http://dx.doi.org/10.1093/noajnl/vdad124

Ejemplares similares